Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gambro buy dents Baxter Q3 profit, but boosts sales

This article was originally published in Clinica

Executive Summary

Baxter International’s third-quarter profits were hit by $111m in costs related to its takeover of hemodialysis specialist Gambro, with earnings falling to $544m, versus $583m during the same period last year. But excluding these charges, income increased 4% to $655m, or $1.19 per diluted share, in line with previous guidance. On the plus side, the Gambro deal, agreed last year (, 4 December 2012), helped boost Baxter’s revenues, which grew 9% year-on-year to $3.77bn. The acquisition finally closed in September, months later than expected. Excluding Gambro’s contribution of $100m, Baxter’s Q3 sales were up 6%. For Q4, the company is predicting revenue growth of 12-13% (14-15% on a constant currency basis), which includes around $400m from Gambro, and earnings of $1.24-1.26 per diluted share. For full-year 2013, Baxter anticipates 6% revenue growth (7% at constant currency), including $500m Gambro sales, and earnings of $4.65-4.67 per diluted share.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts